Literature DB >> 30194803

Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

T J Girard1, K Grunz1, N M Lasky1, J P Malone2, G J Broze1.   

Abstract

Essentials Mouse models are often used to define roles of tissue factor pathway inhibitor (TFPI) in man. TFPI isoform-specific KOs reveal unexpected differences between mouse and human TFPI physiology. Mouse plasma contains 20 times more TFPI than man, derived from TFPIγ, a form not found in man. TFPIγ null mice, expressing only TFPI isoforms α and β, may better reflect the human situation.
SUMMARY: Background Mouse models can provide insight into the pathophysiology of human thrombosis and hemostasis. Tissue factor pathway inhibitor (TFPI) regulates coagulation through protein S (PS)-enhanced factor (F) Xa inhibition and FXa-dependent inhibition of FVIIa/tissue factor (TF) activity. TFPI is expressed as isoforms α and β in man, and α, β and γ in the mouse. Objective Assess the reliability of extending TFPI-related studies in mice to humans. Method Compare mouse and human TFPI physiology using a variety of methods. Results Mouse TFPI and human TFPI are similar in regard to: (i) the mechanisms for FVIIa/TF and FXa inhibition; (ii) TFPIα is a soluble form and TFPIβ is glycosyl phosphatidyl inositol (GPI) membrane anchored; (iii) the predominant circulating form of TFPI in plasma is lipoprotein-associated; (iv) low levels of TFPIα circulate in plasma and increase following heparin treatment; and (v) TFPIα is the isoform in platelets. They differ in that: (i) mouse TFPI circulates at a ~20-fold higher concentration; (ii) mouse lines with isolated isoform deletions show this circulating mouse TFPI is derived from TFPIγ; (iii) sequences homologous to the mouse TFPIγ exon are present in many species, including man, but in primates are unfavorable for splicing; and (iv) tandem mass spectrometry (MS/MS) detects sequences for TFPI isoforms α and β in human plasma and α and γ in mouse plasma. Conclusion To dissect the pathophysiological roles of human TFPIα and TFPIβ, studies in TFPIγ null mice, expressing only α and β, only α or only β should better reflect the human situation.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  alternative splicing; hemostasis; mice; protein isoforms; thrombosis

Mesh:

Substances:

Year:  2018        PMID: 30194803      PMCID: PMC6235150          DOI: 10.1111/jth.14288

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  65 in total

1.  Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.

Authors:  W F Novotny; M Palmier; T C Wun; G J Broze; J P Miletich
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

2.  Characterization of the association of tissue factor pathway inhibitor with human placenta.

Authors:  Alan E Mast; Nayana Acharya; Mark J Malecha; Connie L Hall; Dennis J Dietzen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

3.  The effect of leukocyte elastase on tissue factor pathway inhibitor.

Authors:  D A Higuchi; T C Wun; K M Likert; G J Broze
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

4.  Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.

Authors:  C Augustsson; A Svensson; B Kjaer; T-Y Chao; X Wenjuan; B O Krogh; J Breinholt; J T Clausen; I Hilden; H H Petersen; L C Petersen
Journal:  J Thromb Haemost       Date:  2018-04-06       Impact factor: 5.824

Review 5.  Tissue factor-factor VIIa signaling.

Authors:  L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-29       Impact factor: 8.311

6.  Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.

Authors:  Corina Rosales; Baiba K Gillard; Harry S Courtney; Francisco Blanco-Vaca; Henry J Pownall
Journal:  Biochemistry       Date:  2009-08-25       Impact factor: 3.162

7.  Protein Z, protein Z-dependent protease inhibitor (serpinA10), and the acute-phase response.

Authors:  T J Girard; N M Lasky; E A Tuley; G J Broze
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

8.  Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.

Authors:  T Hamamoto; M Yamamoto; O Nordfang; J G Petersen; D C Foster; W Kisiel
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

9.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.

Authors:  N L Sanders; S P Bajaj; A Zivelin; S I Rapaport
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

10.  Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans.

Authors:  S A Maroney; J P Ferrel; M L Collins; A E Mast
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

View more
  5 in total

1.  Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Authors:  Nadine Müller-Calleja; Anne Hollerbach; Svenja Ritter; Denise G Pedrosa; Dennis Strand; Claudine Graf; Christoph Reinhardt; Susanne Strand; Philippe Poncelet; John H Griffin; Karl J Lackner; Wolfram Ruf
Journal:  Blood       Date:  2019-08-21       Impact factor: 22.113

2.  Defective fibrin deposition and thrombus stability in Bambi-/- mice are mediated by elevated anticoagulant function.

Authors:  James T B Crawley; Argita Zalli; James H Monkman; Anastasis Petri; David A Lane; Josefin Ahnstrom; Isabelle I Salles-Crawley
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

3.  Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model.

Authors:  Debra D Pittman; Swapnil Rakhe; Sheryl R Bowley; Reema Jasuja; Amey Barakat; John E Murphy
Journal:  Res Pract Thromb Haemost       Date:  2022-03-16

4.  The contribution of TFPIα to the hemostatic response to injury in mice.

Authors:  Tanya T Marar; Nicholas D Martinez; Susan A Maroney; Amy E Siebert; Jie Wu; Timothy J Stalker; Maurizio Tomaiuolo; Sinny Delacroix; Robert D Simari; Alan E Mast; Lawrence F Brass
Journal:  J Thromb Haemost       Date:  2021-07-14       Impact factor: 16.036

5.  Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression.

Authors:  Amy E Siebert; Susan A Maroney; Nicholas D Martinez; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-04-12       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.